PEN - Penumbra, Inc.
154.69 0.00 (0.00%)
After hours: 4:28PM EDT
| Previous Close | 152.21 |
| Open | 153.02 |
| Bid | 155.52 x 900 |
| Ask | 155.39 x 900 |
| Day's Range | 150.53 - 156.07 |
| 52 Week Range | 110.84 - 167.35 |
| Volume | 264,508 |
| Avg. Volume | 361,650 |
| Market Cap | 5.361B |
| Beta (3Y Monthly) | 0.96 |
| PE Ratio (TTM) | 859.39 |
| EPS (TTM) | 0.18 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 160.71 |
- Zacks•7 hours ago
Inogen's Prospects in Europe Solid Amid Trade-Related Tension
Inogen's (INGN) business-to-business unit sees strength in Europe.
- Zacks•yesterday
Veeva Systems (VEEV) Gains From Solid Results for Fiscal Q4
Veeva Systems' (VEEV) broad spectrum of products include Veeva Vault, Veeva CRM, Veeva Network and Veeva OpenData.
- Zacks•4 days ago
Integra's Duragen Secures Japanese Nod to Drive Global Growth
Despite facing adverse foreign exchange volatility across its international business, Integra LifeSciences (IART) can successfully eye certain key developments on foreign shores.
- Zacks•5 days ago
Tandem Diabetes (TNDM) Hits a 52-Week High on Solid Prospects
Tandem Diabetes Care's (TNDM) growth in pump shipments drives the top line significantly.
Investor's Business Daily•7 days agoIBD Stock Of The Day: This Medical Stock Jumps Above Key Moving Average
Penumbra stock climbed above key moving averages on Tuesday, as the maker of medical devices was selected as the IBD Stock of The Day. Its products serve neurosurgical and vascular markets.
- Zacks•7 days ago
Haemonetics' Plasma Unit Grows, Global Expansion on Track
Haemonetics' (HAE) Plasma arm steadily witnesses solid growth in the fiscal third quarter on 16% revenue rise at constant currency.
- Zacks•7 days ago
Hill-Rom's Buyout of Voalte to Bolster Digital Connectivity
Hill-Rom (HRC) anticipates Voalte acquisition to be modestly dilutive to its adjusted EPS in fiscal 2019.
- Zacks•8 days ago
Invitae (NVTA) Scales a New 52-Week High on Solid Prospects
One of the key growth drivers for Invitae (NVTA) is an increase in billable tests over the past year.
- Zacks•11 days ago
ResMed's New Brightree Suite to Boost Home Infusion Business
ResMed's (RMD) Brightree suite upgrade will help uplift business operations by easily meeting compliance needs and offering the best quality patient care.
- Zacks•12 days ago
Cooper Companies (COO) Hits 52-Week High on Solid Prospects
Cooper Companies' (COO) revenues across CooperVision and CooperSurgery see growth.
- Zacks•15 days ago
Penumbra (PEN) Earnings and Revenues Beat Estimates in Q4
Penumbra (PEN) sees strength across all segments in Q4.
- Simply Wall St.•18 days ago
Is Penumbra’s Share Price Gain Of 193% Well Earned?
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But in contrast you can make muchRead More...
- Thomson Reuters StreetEvents•18 days ago
Edited Transcript of PEN earnings conference call or presentation 26-Feb-19 9:30pm GMT
Q4 2018 Penumbra Inc Earnings Call
- Zacks•19 days ago
Integra Rides on Channel Expansion Strategy, New Alliances
Integra's (IART) success with its channel expansion strategy and Codman integration buoys investors' optimism on the stock.
- Zacks•19 days ago
ResMed Inks Deal With PharMerica on Medication Management
The deal between ResMed's (RMD) MatrixCare and PharMerica covers NCPDP (National Council for Prescription Drug Programs) Bidirectional ePrescribing with all MatrixCare customer facilities.
- Zacks•20 days ago
DexCom (DXCM) Gets Health Canada Approval for G6 CGM System
DexCom's (DXCM) G6 CGM system intends to serve diabetes patients of all age groups in Canada.
- Zacks•20 days ago
Chemed Gains Ground on Solid VITAS & Roto-Rooter Businesses
Chemed (CHE) witnesses solid revenue growth across key subsidiaries.
Motley Fool•21 days agoPenumbra Inc (PEN) Q4 2018 Earnings Conference Call Transcript
PEN earnings call for the period ending December 31, 2018.
- PR Newswire•21 days ago
Penumbra, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results
ALAMEDA, Calif. , Feb. 26, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full ...
- ACCESSWIRE•21 days ago
Penumbra, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Penumbra, Inc. (NYSE: PEN ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 at 4:30 PM Eastern ...
- Zacks•22 days ago
Here's Why You Should Invest in Illumina (ILMN) Stock Now
Illumina (ILMN) continues to gain on solid international business.
- Zacks•25 days ago
Quest Diagnostics Grows on Innovation Amid Reimbursement Woe
Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.
- Zacks•26 days ago
Masimo and Saudi Arabia MOH Collaborate for CCHD Screening
Studies have shown that Masimo's (MASI) SET pulse oximetry can improve CCHD screening, helping to save newborns.
- Zacks•26 days ago
Luminex Hurt By Segmental Sluggishness, Stiff Competition
Luminex's (LMNX) dependence on its partners for revenue generation is a major problem.
- Zacks•28 days ago
Medtronic Posts Prelim PRODIGY Outcome on Opioid Overdose
The favorable PRODIGY study result by Medtronic (MDT) is undoubtedly a timely, strategic finding.
